CBIO

Crescent Biopharma, Inc. Common Stock
CBIO

Overview Fund Activity

31 hedge funds and large institutions have $109M invested in Crescent Biopharma, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 2 closing their positions.

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
14
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Jacobs Levy Equity Management
1
Jacobs Levy Equity Management
New Jersey
$236K
2
Deutsche Bank
2
Deutsche Bank
Germany
$672K
3
BCM
3
Bridgeway Capital Management
Texas
$479K
4
Renaissance Technologies
4
Renaissance Technologies
New York
$471K
5
Fidelity Investments
5
Fidelity Investments
Massachusetts
$100K

Top Sellers

1
JPMorgan Chase & Co
1
JPMorgan Chase & Co
New York
$0
2
SIM
2
Spark Investment Management
New York
$473K
3
NFA
3
Nationwide Fund Advisors
Ohio
$125K
4
Northern Trust
4
Northern Trust
Illinois
$80K
5
Citigroup
5
Citigroup
New York
$16K
Name Market Value Shares Shares
Change 		Shares
Change %
UBS Group
26
UBS Group
Switzerland
$16K 2,028 +947 +88%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$14K 1,740 – –
BIM
28
BlackRock Investment Management
Delaware
$13K 1,613 +279 +21%
GC
29
Globeflex Capital
California
$1K 83 – –
TCOV
30
Trust Company of Vermont
Vermont
$1K 110 – –
Federated Hermes
31
Federated Hermes
Pennsylvania
$1K 103 +103 New
JPMorgan Chase & Co
32
JPMorgan Chase & Co
New York
– – -75,458 Closed
TRCT
33
Tower Research Capital (TRC)
New York
– – -1 -100%
1
2